EA201791960A1 - Применение лимоннокислого железа в лечении вызванной недостатком железа анемии - Google Patents

Применение лимоннокислого железа в лечении вызванной недостатком железа анемии

Info

Publication number
EA201791960A1
EA201791960A1 EA201791960A EA201791960A EA201791960A1 EA 201791960 A1 EA201791960 A1 EA 201791960A1 EA 201791960 A EA201791960 A EA 201791960A EA 201791960 A EA201791960 A EA 201791960A EA 201791960 A1 EA201791960 A1 EA 201791960A1
Authority
EA
Eurasian Patent Office
Prior art keywords
iron
anemia
induced
iron deficiency
colitis
Prior art date
Application number
EA201791960A
Other languages
English (en)
Russian (ru)
Inventor
Энрике Порадосу
Шай Давид Шемеш
Рон Бентсур
Original Assignee
Керикс Байофармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Керикс Байофармасьютикалз, Инк. filed Critical Керикс Байофармасьютикалз, Инк.
Publication of EA201791960A1 publication Critical patent/EA201791960A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA201791960A 2015-03-04 2016-03-03 Применение лимоннокислого железа в лечении вызванной недостатком железа анемии EA201791960A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127963P 2015-03-04 2015-03-04
PCT/US2016/020575 WO2016141124A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Publications (1)

Publication Number Publication Date
EA201791960A1 true EA201791960A1 (ru) 2018-01-31

Family

ID=56848619

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791960A EA201791960A1 (ru) 2015-03-04 2016-03-03 Применение лимоннокислого железа в лечении вызванной недостатком железа анемии

Country Status (15)

Country Link
US (2) US20180071243A1 (enExample)
EP (1) EP3265077A4 (enExample)
JP (2) JP2018507260A (enExample)
KR (1) KR20170123664A (enExample)
CN (1) CN107530310A (enExample)
AU (1) AU2016226250B2 (enExample)
BR (1) BR112017018963A2 (enExample)
CA (1) CA2978073A1 (enExample)
EA (1) EA201791960A1 (enExample)
HK (2) HK1248589A1 (enExample)
IL (1) IL254125A0 (enExample)
MX (1) MX2017011169A (enExample)
SG (1) SG11201707120PA (enExample)
TW (2) TW202302083A (enExample)
WO (1) WO2016141124A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US20210085711A1 (en) * 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
FR3075601A1 (fr) * 2017-12-21 2019-06-28 Clarisse Le Court Complements alimentaires et leur utilisation sur les menstruations
US12467933B2 (en) 2019-06-07 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Body fluid iron level panel analyzer
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2023047424A1 (en) * 2022-04-29 2023-03-30 West Bengal Chemical Industries Limited Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
CA2552889A1 (en) * 2004-01-14 2005-07-28 Sachiko Suzuki Iron supplement and utilization of the same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2012097155A1 (en) * 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
HK1246649A1 (zh) 2018-09-14
TW202302083A (zh) 2023-01-16
JP2018507260A (ja) 2018-03-15
KR20170123664A (ko) 2017-11-08
WO2016141124A1 (en) 2016-09-09
CN107530310A (zh) 2018-01-02
BR112017018963A2 (pt) 2018-05-15
EP3265077A1 (en) 2018-01-10
HK1248589A1 (zh) 2018-10-19
EP3265077A4 (en) 2018-10-24
TW201639558A (zh) 2016-11-16
TWI812580B (zh) 2023-08-21
US20240075006A1 (en) 2024-03-07
SG11201707120PA (en) 2017-09-28
CA2978073A1 (en) 2016-09-09
MX2017011169A (es) 2017-11-09
JP2021091686A (ja) 2021-06-17
AU2016226250A1 (en) 2017-09-28
IL254125A0 (en) 2017-10-31
US20180071243A1 (en) 2018-03-15
AU2016226250B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201790377A1 (ru) Антитела к глюкагону и их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
BR112015022197A2 (pt) tratamento de cataplexia
MX2017011169A (es) Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro.
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA201500997A1 (ru) Терапевтические применения эмпаглифлозина
MX382077B (es) Polimeros de union a protones para administracion oral.
MY197091A (en) Compositions for treating acid-base disorders
EA202091482A1 (ru) Антитела
EA201890776A1 (ru) Агонисты ppar, соединения, фармацевтические композиции и способы их применения
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
AU2017261919A1 (en) Fat and medical uses thereof
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
BR112018074299A2 (pt) composições farmacêuticas compreendendo eteplirsen
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина